-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[
pharmacy network market analysis] Recently, 65 Chinese companies have already disclosed in 2019 annual reportsAccording to the division Flush Shenyin three industry, which 65 Chinese companies, including 49 oral medicine enterprises (Baiyun Mountain, Tasly, China Resources thirty-nine, etc.), 12 traditional Chinese medicine injection company (step Pharmaceutical, Kunming Pharmaceutical Group, Red medicine industry, etc.) as well as four brand Chinese companies (Pien Tze Huang, Yunnan Baiyao, Tong Ren Tang, wide reputation far)According to statistics, 65 Chinese enterprises in 2019 realized a total revenue of 303.347 billion yuan, an increase of 11.63%; total net profit of 25.147 billion yuan, down 19.48 percentAmong them, oral medicine listed companies total revenue and net profit are accounted for more than half, to 67.90%, 50.85% respectively; while traditional Chinese medicine injections and medicine brands listed company's overall revenue growth rate is below the industry averageChinese Traditional Medicines12 injections total revenue and profit of listed companies are accounted for only 15.65%, 20.28%Chinese medicine injection of listed companies achieved a total revenue of 47.487 billion yuan, an increase of 6.94%, for a total net profit of 5.101 billion yuan, an increase of 11.16 percent, of which, a net loss of pharmaceutical companies, Longin medicine, Jinling Pharmaceutical, Treasure Island net profit fell 273.11%, 36.42%, 12.42% and industry segments away from the net profit growthcan be seen from the data, in 2019, compared to traditional Chinese medicine injection, oral dosage form performance is relatively goodAnalysis of the reasons behind this, mainly traditional Chinese medicine injection is facing increasingly stringent regulatory, drug pressureFrom a policy perspective, the 2017 Legacy Insurance Catalog clear, 26 to limit the use of traditional Chinese medicine injection in secondary and higher medical institutions; in 2019 the new health insurance directory to limit the varieties of traditional Chinese medicine injections increased to 45, including Xuesetong injection, Xueshuantong injection, astragalus Shuxuening injectionIn addition, traditional Chinese medicine injections many times included in the key monitoring and more rational use of medicines catalog to further restrict the use of some varietiesAnd recently, a plurality of varieties of traditional Chinese medicine injection were modified specification2020, although there are a number of traditional Chinese medicine injection is listed as the recommended clinical medicine, but industry experts point out that relying on consumption in the short term these traditional Chinese medicine injection is not enough to drive increased sales throughout the industryon the development of traditional Chinese medicine injection, due to the nature of their problem is safety, efficacy is not clear, currently on the market most of the traditional Chinese medicine injections and no corresponding clinical trial through this, the industry that only the start of traditional Chinese medicine injection listed after the evaluation, to ensure the efficacy and safety through strict quality standard control system, in order to obtain better useSouthwest Securities medicine team believes that the current policy is still tighter industry is expected to injection is also facing decline in sales volume and prices, the outlook is more cautious As the traditional Chinese medicine injection pressure is greater in the current context of medication, and hospitals oral dosage form may replace part of injectables market, compared to under better prospects Specifically, 2019 49 oral medicine enterprises, higher Baiyun Mountain, Tasly, China Resources thirty-nine oral medicine and other business revenue, respectively, to achieve revenues of 64.952 billion yuan, 18.998 billion yuan , 14.702 billion yuan, accounting for revenue were 21.41%, 6.26%, 4.85% On revenue growth point of view, Baiyun Mountain revenue growth rate rose as high as 53.79% on net profit point of view, a higher net profit of Baiyun Mountain, China Resources thirty-nine other enterprises, respectively, to achieve net profit of 3.441 billion yuan, 2.139 billion yuan, net profit accounted for 13.68%, respectively, 8.51 % In addition, the quality of earnings level, 49 oral medicine companies, high net profit level of China Resources Sanjiu net present ratio of 0.92.